Logo image of ANRO

ALTO NEUROSCIENCE INC (ANRO) Stock Fundamental Analysis

NYSE:ANRO - New York Stock Exchange, Inc. - US02157Q1094 - Common Stock - Currency: USD

3.55  -0.4 (-10.13%)

After market: 3.7 +0.15 (+4.23%)

Fundamental Rating

2

Overall ANRO gets a fundamental rating of 2 out of 10. We evaluated ANRO against 192 industry peers in the Pharmaceuticals industry. The financial health of ANRO is average, but there are quite some concerns on its profitability. ANRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ANRO has reported negative net income.
ANRO had a negative operating cash flow in the past year.
ANRO Yearly Net Income VS EBIT VS OCF VS FCFANRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -10M -20M -30M

1.2 Ratios

ANRO has a Return On Assets of -29.98%. This is comparable to the rest of the industry: ANRO outperforms 53.65% of its industry peers.
The Return On Equity of ANRO (-34.81%) is better than 64.58% of its industry peers.
Industry RankSector Rank
ROA -29.98%
ROE -34.81%
ROIC N/A
ROA(3y)-42.77%
ROA(5y)N/A
ROE(3y)-56.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANRO Yearly ROA, ROE, ROICANRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANRO Yearly Profit, Operating, Gross MarginsANRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 -1K -2K -3K -4K -5K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANRO has about the same amount of shares outstanding.
Compared to 1 year ago, ANRO has an improved debt to assets ratio.
ANRO Yearly Shares OutstandingANRO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M 25M
ANRO Yearly Total Debt VS Total AssetsANRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of 1.23, we must say that ANRO is in the distress zone and has some risk of bankruptcy.
ANRO's Altman-Z score of 1.23 is fine compared to the rest of the industry. ANRO outperforms 61.46% of its industry peers.
ANRO has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
ANRO has a Debt to Equity ratio (0.05) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 1.23
ROIC/WACCN/A
WACCN/A
ANRO Yearly LT Debt VS Equity VS FCFANRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 13.09 indicates that ANRO has no problem at all paying its short term obligations.
The Current ratio of ANRO (13.09) is better than 87.50% of its industry peers.
ANRO has a Quick Ratio of 13.09. This indicates that ANRO is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 13.09, ANRO belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.09
Quick Ratio 13.09
ANRO Yearly Current Assets VS Current LiabilitesANRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ANRO have decreased strongly by -31.44% in the last year.
EPS 1Y (TTM)-31.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.43% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y44.72%
EPS Next 2Y20.81%
EPS Next 3Y12.43%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANRO Yearly Revenue VS EstimatesANRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 50K 100K 150K 200K
ANRO Yearly EPS VS EstimatesANRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANRO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANRO Price Earnings VS Forward Price EarningsANRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANRO Per share dataANRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as ANRO's earnings are expected to grow with 12.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.81%
EPS Next 3Y12.43%

More info and screens

0

5. Dividend

5.1 Amount

ANRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTO NEUROSCIENCE INC

NYSE:ANRO (3/7/2025, 8:05:02 PM)

After market: 3.7 +0.15 (+4.23%)

3.55

-0.4 (-10.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-20 2025-03-20/amc
Inst Owners88.31%
Inst Owner Change-1.44%
Ins Owners7.51%
Ins Owner Change0%
Market Cap95.74M
Analysts86.15
Price Target12.04 (239.15%)
Short Float %15.97%
Short Ratio14.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.58%
Min EPS beat(2)6.96%
Max EPS beat(2)12.2%
EPS beat(4)2
Avg EPS beat(4)-99.55%
Min EPS beat(4)-356.11%
Max EPS beat(4)12.2%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.04%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 0.58
EV/EBITDA N/A
EPS(TTM)-9.75
EYN/A
EPS(NY)-2.58
Fwd EYN/A
FCF(TTM)-1.77
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS0
BVpS6.12
TBVpS6.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.98%
ROE -34.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.77%
ROA(5y)N/A
ROE(3y)-56.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 453.07%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.09
Quick Ratio 13.09
Altman-Z 1.23
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)269.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.54%
EPS Next Y44.72%
EPS Next 2Y20.81%
EPS Next 3Y12.43%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-60.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-64.01%
OCF growth 3YN/A
OCF growth 5YN/A